OncoMatch/Clinical Trials/NCT06718543
Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer
Is NCT06718543 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including AK112 with SCRT and CapeOX and AK112 with SCRT for rectal cancer.
Treatment: AK112 with SCRT and CapeOX · AK112 with SCRT — This phase II multicenter, randomized study evaluates the safety and efficacy of neoadjuvant short-course radiotherapy (SCRT) sequentially combined with AK112 (Envafolimab) with or without chemotherapy in patients with locally advanced rectal cancer (LARC). The study also aims to identify biomarkers predicting tumor response and develop efficacy prediction models.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage T3-4NXM0, TXN1-2M0 (MRI assessment)
Clinical baseline stage T3-4NxM0 or TxN1-2M0 by MRI assessment
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: surgery
No prior treatment for rectal cancer, including surgery
Cannot have received: radiotherapy
No prior treatment for rectal cancer, including ... radiotherapy
Cannot have received: chemotherapy
No prior treatment for rectal cancer, including ... chemotherapy
Cannot have received: immunotherapy
No prior treatment for rectal cancer, including ... immunotherapy
Cannot have received: targeted therapy
No prior treatment for rectal cancer, including ... targeted therapy
Lab requirements
Blood counts
Normal organ function
Kidney function
Normal organ function
Liver function
Normal organ function
Normal organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06718543 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T3-4NXM0 or TXN1-2M0 is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages